Abstract:Personalized medicine is revolutionizing cancer detection, characterization, and treatment, however, 30% of children with high-risk cancers lack an actionable molecular target and need alternate approaches to identify personalized treatment recommendations. While mouse patient-derived xenografts (PDXs) are widely regarded as the gold standard for preclinical drug response prediction, they remain highly resource-intensive, challenging to establish, and often have establishment times outside clinically relevant timeframes. The larval zebrafish model has gained prominence as a promising tool for personalized medicine, however, drug treatment responses in zebrafish and mouse PDX models, and in their cognate patients, have not previously been compared. Here, we present data from an international collaboration between two national child cancer precision medicine programs: Canada's PRecision Oncology For Young peopLE (PROFYLE) and Australia's Zero Childhood Cancer (ZERO), which, for the first time, directly compares single agent and combination treatment responses using individualized models in larval zebrafish, mouse, and short-term culture, with patient clinical responses. Samples were collected from ten high-risk childhood/adolescent cancer patients (aged 1.5-15 years) diagnosed with various tumor types and enrolled on ZERO for molecular profiling (whole genome and whole transcriptome sequencing analysis), and in vitro high throughput drug screening (HTS). Mouse PDX drug testing was guided by prior molecular sequencing findings, single agent HTS, and treatments received by each patient. Samples from these patients underwent retrospective zebrafish PDX testing. Labeled tumor cells were engrafted into the zebrafish larvae yolk sac at 48 hours, treated for 3 days from 72 hours by immersion, followed by ex vivo tumor cell quantification for drug response evaluation. Larval zebrafish models were successfully established for all ten patients, including three for whom a mouse PDX model was not able to be developed. Additionally, samples from three of the ten patients underwent a secondary in vitro screen of single drugs and drug combinations, for comparison with responses in larval zebrafish and mouse PDXs. Remarkably, a high degree of concordance was observed between evaluable patient responses and responses observed in preclinical models developed from the patient, with 10/11 zebrafish, 7/8 mouse and 3/3 short-term cultures recapitulating responses in patients. The larval zebrafish workflow was less than one week from engraftment to completion, comparable to direct HTS from patient samples, and far quicker than establishing mouse PDX models. These findings represent the first pediatric precision oncology study to demonstrate consistent and clinically informative drug responses across multiple modalities in successfully predicting drug responses in high-risk child cancer patients, and suggest the feasibility of the larval zebrafish PDX as an efficient preclinical tool for patient-specific therapeutic decision-making. Citation Format: Nadine Azzam, Jamie I. Fletcher, Nicole Melong, Loretta Lau, Emmy M. Dolman, Jie Mao, Gabor Tax, Roxanne Cadiz, Lissandra Tuzi, Alvin Kamili, Biljana Dumevska, Jinhan Xie, Jennifer A. Chan, Donna L. Senger, Stephanie A. Grover, David Malkin, Michelle Haber, Jason N. Berman. High-risk pediatric cancer models in zebrafish, mouse and short-term culture predict individual patient responses to therapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl) nr B007.

Abstract 259: Zebrafish empowered large-scale drug screen to uncover novel targets of self-renewal in T-cell acute lymphoblastic leukemia initiating cells

Overexpression of Notch1 Inducing T-All Phenotype and Promoting Angiogenesis in Zebrafish

Abstract B007: High-risk pediatric cancer models in zebrafish, mouse and short-term culture predict individual patient responses to therapy

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Phenotypically plastic drug‐resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model

A high-throughput zebrafish screen identifies novel candidate treatments for Kaposiform Lymphangiomatosis (KLA)

Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos

In vivo monitoring of leukemia-niche interactions in a zebrafish xenograft model

Advantages of the zebrafish tumor xenograft model: the evaluation of efficacy in cancer therapy and the application to the study of lncRNAs

Transgenic IDH2R172K and IDH2R140Q zebrafish models recapitulated features of human acute myeloid leukemia

A Simple, Highly Visual in Vivo Screen for Anaplastic Lymphoma Kinase Inhibitors.

In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells

Targeting lactate dehydrogenase A ( LDHA ) exerts antileukemic effects on T‐cell acute lymphoblastic leukemia

3138 – A TWO-STEP IN VIVO CRISPR SCREEN UNVEILS PERVASIVE RNA-BINDING PROTEIN DEPENDENCIES FOR LEUKEMIC STEM CELLS AND IDENTIFIES ELAVL1 AS A THERAPEUTIC TARGET

Abstract 3900: A high-throughput platform identifies novel drug combinations towards acute myeloid leukemia therapy

High-Throughput Chemical Screen on Acute Myeloid Leukemia Stem Cells Identifies Novel Anti-LSC Compounds

Long-term non-invasive drug treatments for adult zebrafish

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Abstract 1430: Development of transparent transgenic zebrafish model to study anti-cancer drug induced in vivo cardiotoxicity

Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish

What value do zebrafish have to anticancer drug discovery?